IKNA Company Profile and Key Details

Q: Who are the executives of IKNA?

Dr. Jotin Marango M.D., Ph.D.Chief Financial Officer & Head of Corporation Devel.Mr. Bob LallySenior Vice President of Fin. & OperationsDr. Michelle Zhang Ph.D.Chief Scientific OfficerMr. Evan A. Hecker Ph.D.Senior Vice President & Head of CMCDr. Mark Manfredi Ph.D.Pres. Chief Executive Officer & DirectorDr. Sergio L. Santillana M.B.A., M.D., M.Sc., MScChief Medical OfficerMr. Jeffrey Ecsedy Ph.D.Chief Devel. OfficerMr. Alexander Constan Ph.D.Senior Vice President of Non Clinical Safety & DMPKMr. Alfredo Castro Ph.D.Executive Vice President of DiscoveryMs. Samantha VuksanicHead of HR

NASDAQ : IKNA

Ikena Oncology

$17.16

15.79+1,152.55%

Open: 4:00 PM

Not Actively Trading

60.44

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Ikena Oncology, Inc. (IKNA) stock surged +1,152.55%, trading at $17.16 on NASDAQ, up from the previous close of $1.37. The stock opened at $1.38, fluctuating between $1.36 and $17.16 in the recent session.

Stock Snapshot

1.37

Prev. Close

718.82M

Market Cap

1.36

Day Low

-2.234375

P/E Ratio

-7.68

EPS (TTM)

-1.68

Cash Flow per Share

1.38

Open

41.89M

Number of Shares

17.16

Day High

52.13%

Free Float in %

3.55

Book Value

457.26K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 25, 2025	16.56	17.76	16.32	17.16	457.26K
Jul 24, 2025	16.08	16.68	15.60	16.44	32.14K
Jul 23, 2025	15.60	16.92	15.36	16.56	53.05K
Jul 22, 2025	15.24	15.36	14.40	14.88	1.29M
Jul 21, 2025	15.24	15.48	15.00	15.24	52.41K
Jul 18, 2025	15.36	15.48	14.88	15.24	21.64K
Jul 17, 2025	15.48	15.60	15.12	15.12	42.9K
Jul 16, 2025	16.56	16.56	15.12	15.48	94.74K
Jul 15, 2025	16.80	17.64	16.08	17.04	140.53K
Jul 14, 2025	16.92	17.16	15.96	16.44	14.1K
Jul 11, 2025	16.68	16.80	16.20	16.56	3.36K
Jul 10, 2025	15.84	16.80	15.84	16.68	1.43K
Jul 09, 2025	16.32	16.56	15.72	16.08	16.98K
Jul 08, 2025	16.32	17.04	16.20	16.44	4.97K
Jul 07, 2025	16.20	16.80	16.08	16.20	8.05K
Jul 03, 2025	15.72	16.08	15.72	15.96	674.83
Jul 02, 2025	15.96	16.20	15.72	15.72	3.21K
Jul 01, 2025	16.20	16.20	15.84	15.84	1.04K
Jun 30, 2025	16.32	16.44	15.96	16.08	1.04K
Jun 27, 2025	15.96	16.32	15.96	16.32	2.73K

Contact Details

Boston, MA 02210

United States

https://imagenebio.com 857 273 8343

About Company

Ikena Oncology, Inc. is a biopharmaceutical company specializing in precision oncology. Its primary objective is to create therapeutic agents specifically formulated for patient populations identified through biomarkers, thereby addressing significant unmet medical needs. The company's leading drug candidate is IK-930, an orally administered small molecule designed to inhibit the transcriptional enhanced associate domain (TEAD) transcription factor, a key component of the Hippo signaling pathway. Ikena is also progressing a portfolio of other investigational therapies, including: A small molecule inhibitor program targeting ERK5 within the RAS signaling pathway. IK-175, an oral compound that inhibits the aryl hydrocarbon receptor. IK-007, an orally delivered, selective antagonist of the EP4 receptor, which is being developed for the treatment of microsatellite stable colorectal cancer. Founded in 2016, the company is based in Boston, Massachusetts.

Stock Peers

ARGX

-5.45-0.55%

argenx SE$990.32 REGN

-4.6-0.58%

Regeneron Pharmaceuticals, Inc.$784.85 MDGL

-2.88-0.54%

Madrigal Pharmaceuticals, Inc.$531.52 VRTX

-8.00008-1.55%

Vertex Pharmaceuticals Incorporated$508.34 UTHR

-2.64-0.53%

United Therapeutics Corporation$494.63 ONC

-2.62-0.74%

BeOne Medicines AG$350.84 KRYS

-2.08-0.61%

Krystal Biotech, Inc.$336.67 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

-11.52-3.71%

Praxis Precision Medicines, Inc.$298.95 LGND

-1.21-0.43%

Ligand Pharmaceuticals Incorporated$283.49

Company Overview

Ikena Oncology, Inc. (NASDAQ:IKNA) closed at $17.16 USD, gaining $15.79 (1,152.55%) from the previous close of $1.37. The stock is currently mid-range between its 52-week high and low $1.36 and $23.28. With a market capitalization of about $718.82 million, Ikena Oncology, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.50). Key stats such as the average daily volume over the past year has been around 18.00 thousand shares, trading with heavier-than-usual volume. Headquartered in Boston, MA, Ikena Oncology, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Mark Manfredi, the company employs approximately 10 people and listed since March 26, 2021. Ikena Oncology, Inc. is a biopharmaceutical company specializing in precision oncology.

Technical Performance

IKNA has shown sold momentum, gaining 12.6% over the past week and 18.18% over the past quarter, though year-to-date performance is down -12.8%. Short-term trend indicators are mixed aligned (SMA20 6.76%, SMA50 9.87%, SMA200 -0.45%). The stock’s 14-day RSI is 59.83 (neutral), while the ATR of 0.96 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -26.29% below its high and over 47.32% above its low.

Dividend & Fair Value

Ikena Oncology, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.66. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Ikena Oncology, Inc. generated EPS of -$7.65 over the past year. Five-year average earnings growth is -16.81%. Wall Street analysts project EPS growth of 0.0% annually over the next five years. The latest quarter delivered EPS of -$0.53. The next quarter is forecast at -$1.14. Next year's EPS is expected at -$15.67. Ikena Oncology, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 06, 2025, missed forecasts by 308.46%. The prior quarter beat by -57.14%. Over the last six quarters, Apple has recorded several small beats. These include -12.9% in August 08, 2024.

Shareholding & Insider Activity

Ikena Oncology, Inc. has 48.26 million shares outstanding. The public float is 13.87 million shares, elevated short interest at 0.34% of float. This equals 130.17 thousand shares. The short ratio is 0.28 days. Institutional investors hold 82.84% of the float. Insiders own 8.0%. Bonita David P holds 2.00 million shares, ORBIMED ADVISORS LLC has 2.00 million shares and OrbiMed Genesis GP LLC has 1.91 million shares.

Financial & Profitability Overview

Over the trailing twelve months, Ikena Oncology generated $9.16M in revenue, or $0.22 per share. Gross margin was 88.86%, operating margin -823.33%, and net profit margin -744.17%. Returns are negative, with ROA at -35.49% and ROE at -40.16%.
On valuation metrics, Ikena Oncology trades at a P/E of -12.81, P/S of 0.00 and P/B of 1.95. The current ratio is 21.47 and quick ratio is 21.47. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is 2049.45 days. Debt-to-equity is 0.01, supported by a cash flow-to-debt ratio of -30.20.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Ikena Oncology posted revenue of $9.16M, down slightly from $15.62M in the prior quarter. Gross profit was $8.14M (margin 88.86%). Operating income was - $75.42M (margin -823.3%). Net income was- $68.17M (EPS - $1.63).
The company ended the quarter with $175.47M in cash and short-term investments, a total debt of $10.74M, and net debt of - $109.16M. Total assets were $192.09M, with equity of $169.76M. Financials further reflected weakness, with operating cash flow of - $79.74M, free cash flow of - $80.16M, and capital expenditures of - $414.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Ikena Oncology, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -91.9%, with price expected at $1.39 by August 08, 2025, within a range of $1.34 to $1.44 3-Month Outlook: Projected fall of -95.22%, reaching $0.82 by October 23, 2025, with a range of $0.77 to $0.87. 1-Year Outlook: Projected loss of -93.3%, with price at $1.15 by July 24, 2026, within a range of $0.00 to $0.00.

Key Takeaways

Ikena Oncology, Inc. (NASDAQ:IKNA) shares are down -12.8% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Ikena Oncology, Inc. trading at a premium to the broader market with a P/E of -12.81. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $18.25, suggesting 6.35% upside. Our AI forecast model points to short-term weakness (-91.9% over two weeks), a medium-term fall (-95.22% over three months), and a longer-term loss (-93.3% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Ikena Oncology, Inc. (IKNA) stock price?

Ikena Oncology, Inc. (NASDAQ: IKNA) stock price is $17.16 in the last trading session. During the trading session, IKNA stock reached the peak price of $17.16 while $1.36 was the lowest point it dropped to. The percentage change in IKNA stock occurred in the recent session was 1,152.55% while the dollar amount for the price change in IKNA stock was $15.79.

IKNA's industry and sector of operation?

The NASDAQ listed IKNA is part of Biotechnology industry that operates in the broader Healthcare sector. Ikena Oncology, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of IKNA?

Dr. Jotin Marango M.D., Ph.D.
Chief Financial Officer & Head of Corporation Devel.
Mr. Bob Lally
Senior Vice President of Fin. & Operations
Dr. Michelle Zhang Ph.D.
Chief Scientific Officer
Mr. Evan A. Hecker Ph.D.
Senior Vice President & Head of CMC
Dr. Mark Manfredi Ph.D.
Pres. Chief Executive Officer & Director
Dr. Sergio L. Santillana M.B.A., M.D., M.Sc., MSc
Chief Medical Officer
Mr. Jeffrey Ecsedy Ph.D.
Chief Devel. Officer
Mr. Alexander Constan Ph.D.
Senior Vice President of Non Clinical Safety & DMPK
Mr. Alfredo Castro Ph.D.
Executive Vice President of Discovery
Ms. Samantha Vuksanic
Head of HR

How IKNA did perform over past 52-week?

IKNA's closing price is 1,161.77% higher than its 52-week low of $1.36 where as its distance from 52-week high of $23.28 is -26.29%.

How many employees does IKNA have?

Number of IKNA employees currently stands at 10.

Link for IKNA official website?

Official Website of IKNA is: https://imagenebio.com

How do I contact IKNA?

IKNA could be contacted at phone 857 273 8343 and can also be accessed through its website. IKNA operates from 645 Summer Street, Boston, MA 02210, United States.

How many shares of IKNA are traded daily?

IKNA stock volume for the day was 457.26K shares. The average number of IKNA shares traded daily for last 3 months was 18K.

What is the market cap of IKNA currently?

The market value of IKNA currently stands at $718.82M with its latest stock price at $17.16 and 41.89M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	10
Beta	0.5
Sales or Revenue	$9.16M
5Y Sales Change%	6.948%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

IKNA Company Profile and Key Details

Ikena Oncology

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Stock Snapshot

Earnings & Analyst Outlook

Shareholding & Insider Activity

Company Overview

Technical Performance

Price Forecast & Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Key Takeaways